Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
ELF™ Testing at Nordic Bioscience
November 25, 2025
At Nordic Bioscience, we provide central and specialty lab services that encompass a broad range of diagnostic and exploratory tests such as the ELF™ (Enhanced Liver Fibrosis) test.
What is the ELF™ Test?
The ELF™ test is available on our high-throughput Siemens Atellica IM® platform, where it brings together three direct extracellular-matrix biomarkers into a validated composite score: HA, PIIINP, and TIMP-1.
The analytes are automatically measured, and the software calculates and reports a unitless numeric score. Increasing ELF scores are linked to both biopsy-proven fibrosis and prognosis for clinically significant outcomes.
The ELF scoring system – Severity assessment (against biopsy-proven fibrosis)
| None to Mild | Score: <7.7 |
| Moderate | Score: ≥7.7 to <9.8 |
| Severe | Score: ≥9.8 (associated with high risk of significant fibrosis) |
| Cirrhosis | Score: ≥11.3* |
These insights help clinicians and researchers to assess fibrosis severity and stratify risk in metabolic and chronic liver diseases, including MASLD/NAFLD.
Why measure with us?
- Efficient sample requirements – We require just 165 µL of serum, reducing patient burden and supporting streamlined sampling in both clinical practice and study settings.
- Excellent long-term sample stability – Samples are stable for up to 25 months at ≤ –70°C (in-house data) and up to 3 years according to published literature which is ideal for global trials and multi-site studies
- Integrated biomarker strategy – ELF is complemented by nordicPRO-C3™, our collagen formation biomarker that reflects active fibrogenesis, offering a dual perspective.
This creates a more complete fibrosis profile than traditional liver enzymes alone (ASAT, ALAT), enabling more confident interpretation and decision-making.
